Carol Suh is a Partner with ARCH Venture Partners. She joined ARCH in 2018 as an Associate and was named Partner in 2021. At ARCH, Carol invests in and builds new companies across multiple therapeutic modalities, including cell and gene therapy, neuroscience, oncology and immunology. Carol helped create and invest in multiple high-impact ventures, including co-founding Orbital Therapeutics, an RNA medicines company (acquired by Bristol Myer-Squibb), and investing in HI-Bio, a clinical-stage immunology company (acquired by Biogen). She also co-founded and served as Chief Operating Officer at Neumora Therapeutics (NASDAQ: NMRA), helping scale the company from inception to a public clinical-stage leader in neuroscience.
Prior to ARCH, Carol was a consultant at Trinity Partners, working with a wide range of biotech and pharma companies on corporate strategy, market research and business development. She began her career in R&D Strategy with GlaxoSmithKline’s Regenerative Medicine group.
Carol is a founding board member of the nonprofit CODA (Complex Disorders Alliance), which is advancing research for complex chronic disorders that impact multiple body systems. She has received numerous awards for her work in biotech, including the National Venture Capital Association (NVCA)’s 2026 Rising Star Award, San Francisco Business Times’ 40 Under 40 in 2026, Endpoints News’ 20 Under 40 in 2021 and Forbes’ 30 Under 30 in 2015.
Carol is a stem cell biologist by training, combining her scientific expertise with experience on the business side of biotech. She holds an A.B. in molecular and cellular biology from Harvard University, where she trained under Dr. David Scadden at the Harvard Stem Cell Institute. Carol holds an M.Phil from Yale University, where she was awarded the National Science Foundation Graduate Research Fellowship for her work in stem cell biology. She also completed her M.B.A. at the Stanford Graduate School of Business.